Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table 1. Study stratification and dosing regimen; Supplementary Table 2. p53 target genes examined in this study; Supplementary Table 3. Characteristics of evaluable patients treated at the MTD; Supplementary Table 4. Patient demographic data by cohort; Supplementary Table 5. Adverse events by grade observed in > 10% of the patients/stratum; Supplementary Table 6. Stratum pharmacokinetic parameters based on RG7112 dose regimen and formulation; Supplementary Table 7. Summary of steady state AUC for AML patients treated at the MTD; Supplementary Table 8. Clinical activity for patients with p53 mutations
Authors: Michael Andreeff, Kevin R. Kelly, Karen Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David Bowen, Giovanni Martinelli, Mark W. Drummond, Paresh Vyas, Mark Kirschbaum, Swaminathan Padmanabhan Iyer, Vivian Ruvolo, Graciela M. Nogueras González, Xuelin Huang, Gong Chen, Bradford Graves, Steven Blotner, Peter Bridge, Lori Jukofsky, Steve Middleton, Monica Reckner, Ruediger Rueger, Jianguo Zhi, Gwen Nichols, Kensuke Kojima
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362399554